Western Yilgarn NL (ASX: WYX) has executed new land access agreements over Zones 100 and 200 at its West Julimar Bauxite Project in the Darling Range of Western Australia (Figure 1). These agreements provide access to extensive areas of lateritic bauxite immediately adjoining and between the Company’s existing JORC-compliant Mineral Resource areas, opening a clear pathway for potential resource expansion.

Terra Critical Minerals Limited (ASX: T92) has closed the acquisition of the 100%-owned True American Tungsten Project, located in central Nevada, USA. The transaction marks Terra’s formal entry into the U.S. tungsten space, securing a historically high-grade project within a recognised mining jurisdiction and positioning the Company for on-the-ground work programs in 2026.

Island Pharmaceuticals Limited (ASX: ILA) is advancing its antiviral strategy through the clinical development of Galidesivir, a broad-spectrum antiviral targeting high-consequence viral threats, including Marburg and Ebola. The program is positioned within a global biosecurity and public health framework, with regulatory engagement centred on the United States Food and Drug Administration (FDA) and potential inclusion in government stockpiles.

IRIS Metals Limited (ASX: IR1) has reported high-grade rubidium assay results from its 2023 and 2024 drilling programs at the Beecher Project, located in the southern Black Hills of South Dakota, USA (Figure 1). The results confirm a significant rubidium discovery alongside the project’s established lithium resource, further positioning Beecher as a multi-commodity critical minerals asset in a mining-friendly U.S. jurisdiction.

Miramar Resources Limited (ASX: M2R) has outlined plans to commence drilling across multiple high-priority targets during the first quarter of 2026, spanning gold exploration at its 80%-owned Gidji JV Project near Kalgoorlie and base metal exploration at the Chain Pool Project in the Gascoyne region of Western Australia.

AuMEGA Metals Ltd (ASX: AAM) has reported the results of its 2025 surficial till geochemistry and geological mapping program at the Bunker Hill Project, located within the Company’s 110-kilometre district-scale landholding along the Cape Ray Shear Zone (CRSZ) in southwestern Newfoundland, Canada. The work provides a materially improved understanding of structural controls, system scale, and target prioritisation across Bunker Hill, reinforcing the project’s underexplored pote

BCAL Diagnostics is transitioning from a long-standing research-led organisation into a commercial early cancer diagnostics company, with laboratory operations based in Sydney and expanding national reach across Australia. The Company’s FY25 AGM and its 9 December 2025 ASX announcement collectively outline a business now focused on scaling commercial adoption following the launch of its first diagnostic product and the upcoming national rollout of additional early-detection t

The Australian healthcare sector continues to attract investor attention as companies progress from early development into clinical validation, regulatory approval, and commercial execution. This ASX Companies Snapshot & Market Position provides a concise, side-by-side overview of selected ASX-listed healthcare companies, outlining what each business does, where it sits within the market, and how it is currently positioned from a market capitalisation and execution perspectiv

Adisyn Ltd (ASX: AI1) is advancing a graphene-based semiconductor technology platform through its wholly owned subsidiary, 2D Generation (2DG), supported by international research collaborations across Israel, Europe, and the United States. The Company’s core development work focuses on low-temperature graphene deposition processes designed for compatibility with existing semiconductor manufacturing environments.

Proteomics International Laboratories Ltd (ASX: PIQ), based in Perth, Western Australia, has announced a major intellectual property milestone with the granting of a United States patent for its PromarkerEso diagnostic test (Figure 1). The patent strengthens the Company’s position in the world’s largest healthcare market and supports the commercialisation pathway for a first-in-class blood test targeting esophageal adenocarcinoma (EAC), a cancer with poor survival outcomes wh